CVRx, Inc. lowered its 2026 revenue guidance from $63-$67 million to $58-$60 million due to sales team turnover, onboarding issues, and reimbursement challenges with a major Medicare Advantage payer. The company also disclosed receiving a Department of Justice civil investigative demand related to sales and marketing practices. Law firm Johnson Fistel, PLLP is investigating whether CVRx or its executives misled investors or failed to disclose material information timely, potentially violating securities laws. Investors who suffered losses are encouraged to join the investigation as legal actions may follow.
Tesla has increased its control of the U.S. electric vehicle (EV) market to 59%, marking its highest market share since 2023. This growth highlights Tesla's strong position and continued dominance in the competitive EV industry. The increased market ...
Last week, US-listed Bitcoin and Ethereum exchange-traded funds (ETFs) recorded their largest weekly inflows since October 2025, attracting a combined $2.6 billion. Bitcoin ETFs led with $1.92 billion, while Ethereum ETFs added $697 million, reversin...
XRP surged 10% in the last 24 hours, pushing its weekly gains beyond 50%, driven by a broader crypto market rally after the U.S. Treasury doubled bond buybacks. Asset manager 21Shares highlighted four key structural changes in XRP's ecosystem, includ...
USDe is a synthetic dollar token whose yield derives from a delta-neutral derivatives trading position, not from interest on dollar reserves. The German regulator BaFin ordered Ethena GmbH, the issuer, to wind down its authorisation-requiring busines...
JPMorgan's JEPI ETF, known for monthly income via covered calls on large caps, faces competition from BlackRock's BALI ETF. Both charge 0.35% and pay monthly, but BALI offers a higher trailing yield of 7.56% versus JEPI's similar payout and has outpe...
